| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1007/S11882-996-0014-7 |
| P698 | PubMed publication ID | 16899203 |
| P50 | author | Giorgio Walter Canonica | Q56380976 |
| Giovanni Passalacqua | Q61949008 | ||
| P2093 | author name string | Enrico Compalati | |
| Laura Guerra | |||
| Arianna Cirillo | |||
| Federica Fumagalli | |||
| P2860 | cites work | Long-term clinical efficacy of grass-pollen immunotherapy | Q33870492 |
| Allergic rhinitis and its impact on asthma | Q34438438 | ||
| Immune mechanisms of allergen-specific sublingual immunotherapy | Q34484071 | ||
| Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis | Q34566680 | ||
| Noninjection routes for immunotherapy | Q35087289 | ||
| Efficacy and safety of sublingual immunotherapy | Q35849524 | ||
| Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis | Q35970094 | ||
| The safety of sublingual-swallow immunotherapy: an analysis of published studies | Q36130311 | ||
| Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study | Q39581669 | ||
| Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. | Q40502002 | ||
| Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis | Q40523833 | ||
| Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis | Q40523843 | ||
| Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study | Q40544021 | ||
| Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). | Q40588482 | ||
| Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule | Q42662221 | ||
| Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study | Q43646876 | ||
| Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. | Q43724345 | ||
| Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites | Q44290592 | ||
| Specific immunotherapy with a standardized latex extract in allergic workers: A double-blind, placebo-controlled study | Q44438848 | ||
| Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate | Q44680424 | ||
| Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial | Q44961338 | ||
| Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more | Q45088211 | ||
| Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study | Q46531626 | ||
| Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy. | Q46714664 | ||
| Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis | Q46892026 | ||
| Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production | Q46961926 | ||
| Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen. | Q47366996 | ||
| Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers | Q47715881 | ||
| Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study | Q47776229 | ||
| Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years | Q47795423 | ||
| Safety of sublingual immunotherapy with a monomeric allergoid in very young children. | Q47886315 | ||
| Safety of sublingual immunotherapy in children with asthma. | Q51646876 | ||
| Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. | Q51686636 | ||
| Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. | Q51719532 | ||
| Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study. | Q51728271 | ||
| Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. | Q52935226 | ||
| Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. | Q52940754 | ||
| A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. | Q52942005 | ||
| Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. | Q53551598 | ||
| Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. | Q54423199 | ||
| Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites | Q60809793 | ||
| Position paper: Immunotherapy | Q72860301 | ||
| Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients | Q73120444 | ||
| Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial | Q73154680 | ||
| House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study | Q73227136 | ||
| Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers | Q73417204 | ||
| Immunomodulation during sublingual therapy in allergic children | Q73481524 | ||
| A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship | Q73537804 | ||
| Sublingual swallow or spit? | Q74079058 | ||
| Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis | Q74309230 | ||
| Sublingual desensitization: a new approach to latex allergy problem | Q78290212 | ||
| Randomized open comparison of the safety of SLIT in a no-updosing and traditional updosing schedule in patients with Parietaria allergy | Q79811950 | ||
| Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy | Q79917788 | ||
| Incorrect allergy injections: allergists' experiences and recommendations for prevention | Q80224022 | ||
| Quantitative assessment of the adherence to sublingual immunotherapy | Q80235451 | ||
| Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report | Q81047272 | ||
| Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis | Q81055255 | ||
| Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years | Q81301079 | ||
| Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract | Q81454014 | ||
| Children's compliance with allergen immunotherapy according to administration routes | Q81595002 | ||
| A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma | Q81738036 | ||
| Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children | Q82065255 | ||
| Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan | Q82223243 | ||
| Allergen-specific sublingual immunotherapy: less mystic, more scientific | Q82247188 | ||
| Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year) | Q83186659 | ||
| P433 | issue | 5 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 407-412 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | Current Allergy and Asthma Reports | Q2246111 |
| P1476 | title | New insights in sublingual immunotherapy | |
| P478 | volume | 6 |
| Q37567423 | Therapeutic manipulation of immune tolerance in allergic disease | cites work | P2860 |
Search more.